News | August 13, 2025
Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
NewCo’s pipeline includes five investigational medicines
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Subscribe To Our Newsletter & Stay Updated
